Becton, Dickinson and Company $BDX Stock Position Lessened by Park National Corp OH

05 Oct 2026, 13:37 by Teresa Graham · The Cerbat Gem

Park National Corp OH lessened its holdings in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 18.3% during the 3rd quarter, Holdings Channel reports. The firm owned 48,535 shares of the medical instruments supplier’s stock after selling 10,859 shares during the period. Park National Corp OH’s holdings in Becton, Dickinson and Company were worth $8,688,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the company. BlackRock Inc. acquired a new position in Becton, Dickinson and Company in the second quarter valued at $3,721,533,000. State Street Corp raised its position in Becton, Dickinson and Company by 8.5% in the second quarter. State Street Corp now owns 15,000,064 shares of the medical instruments supplier’s stock worth $2,269,960,000 after acquiring an additional 1,177,256 shares in the last quarter. First Eagle Investment Management LLC lifted its position in shares of Becton, Dickinson and Company by 15.8% during the 2nd quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock valued at $2,090,675,000 after acquiring an additional 1,887,224 shares during the period. Auto Owners Insurance Co increased its position in shares of Becton, Dickinson and Company by 22,225.2% in the fourth quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock valued at $790,079,000 after buying an additional 40,528,680 shares in the last quarter. Finally, Bank of America Corp DE acquired a new position in Becton, Dickinson and Company during the second quarter worth about $474,993,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock traded up $2.60 during trading on Monday, reaching $179.40. 478,562 shares of the company’s stock were exchanged, compared to its average volume of 2,505,086. The firm’s 50-day moving average price is $180.69 and its 200 day moving average price is $161.72. The company has a market cap of $49.43 billion, a P/E ratio of 54.03, a PEG ratio of 11.92 and a beta of 0.21. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $193.07. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The firm had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, research analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th were given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend was Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is presently 126.51%.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the transaction, the executive vice president owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Thomas Polen, Jr. sold 4,152 shares of the stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $20,380,155. This represents a 3.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 6,906 shares of company stock valued at $1,265,855 over the last ninety days. 0.40% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

BDX has been the topic of several recent research reports. Bank of America upped their price objective on Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Monday, August 31st. Weiss Ratings upgraded Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, September 28th. Jefferies Financial Group reiterated a “buy” rating and set a $210.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Piper Sandler upped their target price on Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Finally, TD Cowen raised their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Eight investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $187.67.

Check Out Our Latest Stock Report on BDX

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.